J. Heyckendorf (Hamburg, Germany), A. Garcia-Basteiro (Maputo, Mozambique)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
New definitions of extensively drug resistant tuberculosis: update from the World Health Organization
K. Viney (Geneva, Switzerland), F. Mirzayev (Geneva, Switzerland), N. Linh (Geneva, Switzerland), M. Gegea (Geneva, Switzerland), M. Zignol (Geneva, Switzerland)
|    |
Outcomes of modified all-oral 9-month treatment regimen for rifampicin-resistant tuberculosis in Belarus
N. Yatskevich (Minsk, Belarus), E. Gurbanova (Tartu, Estonia), H. Hurevich (Minsk, Belarus), M. Dara (Copenhagen, Denmark), A. Yedilbayev (Copenhagen, Denmark), V. Grankov (Copenhagen, Denmark), O. Gozalov (Copenhagen, Denmark), A. Skrahina (Minsk, Belarus)
| |
Metformin as an adjunct in treatment of Pulmonary Tuberculosis in Non-Diabetic patients.
S. Pothal (Sambalpur (Odisha), India), I. Samantaray (Sambalpur (Odisha), India), S. Biswal (Sambalpur (Odisha), India)
| |
Treatment failure of nontuberculosis pulmonary disease after adjunctive surgical resection
N. Kang (Seoul, Republic of Korea), B. Jhun (Seoul, Republic of Korea)
| |
Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.
R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark)
| |
Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis.
A. Pakhlavonova (Moscow, Russian Federation), V. Aksenova (Moscow, Russian Federation), N. Klevno (Moscow, Russian Federation), A. Kazakov (Moscow, Russian Federation), S. Popov (Moscow, Russian Federation), V. Hotchenkov (Moscow, Russian Federation), A. Ruzhitsky (Moscow, Russian Federation)
|  |
Barriers and enablers to implementing TB control strategies in EU and EEA countries: a systematic review
O. Conroy (London, United Kingdom), F. Wurie (London, United Kingdom), S. Collin (London, United Kingdom), M. Edmunds (London, United Kingdom), G. De Vries (The Hague, Netherlands), K. Lönnroth (Stockholm, Sweden), I. Abubakar (London, United Kingdom), S. Anderson (London, United Kingdom), D. Zenner (London, United Kingdom)
| |
Impact of pulmonary tuberculosis on COPD outcomes
N. Faria (Porto, Portugal), M. Costa (Porto, Portugal), J. Gomes (Porto, Portugal), M. Sucena (Porto, Portugal)
| |
Tuberculosis in the elderly. Clinical aspects and outcomes.
E. Garay Llorente (Bilbao (Bizkaia), Spain), E. Tabernero Huguet (Bilbao (Bizkaia), Spain), T. Rodrigo Sanz (SEPAR, Spain), L. Altube Urrengoetxea (Bilbao (Bizkaia), Spain), J. Medina Gallardo (Sevilla, Spain), N. Ortiz Laza (Bilbao (Bizkaia), Spain), J. Garros Garay (Bilbao (Bizkaia), Spain), J. Rodriguez Lopez (Aviles, Spain), J. Garcia Garcia (SEPAR, Spain), P. Separ (SEPAR, Spain), E. Garay Llorente (Barakaldo, Spain)
| |
Late Breaking Abstract - Impact of the SARS-CoV-2 pandemic on incidence and phenotype of tuberculosis in a UK hotspot
J. Kim (Leicester, United Kingdom), R. Patel (Leicester, United Kingdom), D. Bell (Leicester, United Kingdom), M. Pareek (Leicester, United Kingdom), H. Thuraisingam (Leicester, United Kingdom), J. Lee (Leicester, United Kingdom), A. Gilmour-Caunt (Leicester, United Kingdom), L. Yorke (Leicester, United Kingdom), G. Woltmann (Leicester, United Kingdom), R. Verma (Leicester, United Kingdom), P. Haldar (Leicester, United Kingdom)
| |
Discussion
| |